Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost

Camille Bédard(Université Laval), Christian R. Landry(PROTEO), Jonathan Boisvert(PROTEO), Anna Fijarczyk(PROTEO), Jehoshua Sharma(University of Guelph), Alexandre K. Dubé(PROTEO), Isabelle Gagnon‐Arsenault(PROTEO), Laetitia Maroc(University of Guelph), Samuel Plante(PROTEO), Rebecca S. Shapiro(University of Guelph), Alicia Pageau(PROTEO)
Nature Microbiology
October 8, 2024
Cited by 42


Related Papers